SCHEMBL6985290

SCHEMBL6985290

N#Cc1ccc(CCC(=O)N2CCCc3cc(S(=O)(=O)NCc4ccccc4)ccc32)cc1

nearest known ligand 0.63

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.58
KMT2A Q03164 3/20 0.58
HTT P42858 2/20 0.58
LMNA P02545 2/20 0.58
MEN1 O00255 2/20 0.58
MAPT P10636 2/20 0.56
TP53 P04637 3/20 0.53
CYP2C9 P11712 1/20 0.50
HPGD P15428 1/20 0.50
CYP2C19 P33261 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
CYP19A1 P11511 1/20 0.47
MAPK1 P28482 2/20 0.46
PRMT1 Q99873 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6986976 0.89 ADRB2 (0.58) ALDH1A1KMT2ALMNAMEN1HPGD
SCHEMBL7410691 0.87 ALDH1A1 (0.54) ALDH1A1KMT2AHTTLMNAMEN1
SCHEMBL6983746 0.86 NR3C1 (0.47) ALDH1A1KMT2ALMNAMEN1CYP2C9
Hydrochloric Acid SCHEMBL6985275 0.85 ALDH1A1 (0.55) ALDH1A1KMT2AHTTLMNAMEN1
SCHEMBL6976631 0.84 HSD17B3 (0.46) ALDH1A1KMT2AMEN1MAPTTP53
SCHEMBL6981640 0.83 NR3C1 (0.47) ALDH1A1KMT2AHTTLMNAMEN1
SCHEMBL6985317 0.83 NR3C1 (0.58) KMT2ALMNAMEN1MAPTTP53
SCHEMBL6985295 0.82 MAPT (0.45) ALDH1A1KMT2AHTTLMNAMEN1
SCHEMBL6985562 0.81 NR3C1 (0.56) ALDH1A1KMT2AMEN1HPGDSMN1; SMN2
SCHEMBL6977969 0.81 NR3C1 (0.56) ALDH1A1KMT2AMEN1MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0991624-B1 PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT BOEHRINGER INGELHEIM PHARMA (DE) 2003-11-19 EP disclosed
US-6300342-B1 FOR THERAPY OR INHIBITING THROMBUS FORMATION; FOR THERAPY OF FIBRIN-DEPENDENT INFLAMMATORY CONDITION BOEHRINGER INGELHEIM PHARM KG (DE) 2001-10-09 US disclosed